SOURCE: The Bedford Report

The Bedford Report

June 27, 2011 08:16 ET

Fierce Competition Prompts Changes for Rite Aid and Walgreen

The Bedford Report Provides Equity Research on Rite Aid & Walgreen

NEW YORK, NY--(Marketwire - Jun 27, 2011) - The economic recovery seems to be having a positive effect on the Drug Stores sector. Same store sales rose for many companies during the most recent quarter. This was spurred by growth in pharmacy sales volumes as nearly the entire sector saw itself filling more prescriptions. Some generic introductions hurt total revenues, however. The Bedford Report examines the outlook for companies in the Drug Stores Industry and provides investment research on Rite Aid Corporation (NYSE: RAD) and Walgreen Co. (NYSE: WAG). Access to the full company reports can be found at:

With fierce competition in the Drug Stores industry, companies are investing a great deal of money to bolster their product offerings as well as their in-store experience through re-models. All this is in hopes of attracting more customers to come buy similar products.

In the most recent quarter, Walgreen said that selling, general and administrative (SG&A) expenses skyrocketed more than 7 percent year over year to $4.2 billion. The company said that it opened or acquired 41 new drugstores (a net gain of 25 after relocations and closings) in the third quarter.

The Bedford Report releases equity research on the Drug Store Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Last week Rite Aid posted a net loss of $63.1 million in the first quarter of fiscal 2012 compared with a loss of $73.7 million in the year-ago period. During the company's earnings call, Rite Aid CEO, John Standley said the drug store plans to fuel growth by increasingly administering the immunizations Americans used to receive from their personal physicians. Rite Aid expects to more than double its injections this fiscal year to some 1.5 million.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

Contact Information